Blockade of pancreatic polypeptide-sensitive neuropeptide Y (NPY) receptors by agonist peptides is prevented by modulators of sodium transport. Implications for receptor signaling and regulation.
Ligand binding to rodent pancreatic polypeptide-responding neuropeptide Y (NPY) receptors (here termed PP/NPY receptors), or to cloned Y4 or Y5 receptors, is selectively inhibited by amiloride, peptide or alkylating modulators of sodium transport. The PP/NPY and Y4 receptors are also selectively blocked by human or rat pancreatic polypeptide (PP) and the blocking peptides are not dissociated by high concentrations of alkali chlorides (which restore most of the binding of subtype-selective agonists to Y1 and Y2 sites). The PP/NPY receptors could also be blocked by NPY and related full-length peptides, including Y1-selective agonists (IC50 300-400 pM). The cloned Y(4) receptors from three species are much less sensitive to NPY or PYY. The sensitivity of both the PP/NPY sites and the Y(4) sites to Y2-selective peptides is quite low. The ligand attachment to PP/NPY sites is also very sensitive to peptidic Y1 antagonist ((Cys31,NVal34NPY27-36))2, which however blocks these sites at much higher molarities. Blockade of PP/NPY and Y4 sites by agonist peptides can be largely prevented by N5-substituted amiloride modulators of Na+ transport, and by RFamide NRNFLRF.NH2, but not by Ca2+ channel blockers, or by inhibitors of K+ transport. Protection of both PP/NPY and Y4 sites against blockade by human or rat pancreatic polypeptide is also afforded by short N-terminally truncated NPY-related peptides. The above results are consistent with a stringent and selective activity regulation for rabbit PP/NPY receptor(s) that may serve to differentiate agonists and constrain signaling, and could involve transporter-like interactants.
Parker
M S
MS
Department of Microbiology and Molecular Cell Sciences, University of Memphis, Memphis, TN 38163, USA. slparker@utmem.edu
Berglund
M M
MM
Lundell
I
I
Parker
S L
SL
D000818:Animals; D001665:Binding Sites; D001667:Binding, Competitive; D001692:Biological Transport; D001921:Brain / Q000378:metabolism; D016466:CHO Cells; D015220:Calcium Channels / Q000378:metabolism; D003001:Cloning, Molecular; D006224:Cricetinae; D004305:Dose-Response Relationship, Drug; D006801:Humans; D020128:Inhibitory Concentration 50; D007668:Kidney / Q000378:metabolism; D007672:Kidney Cortex / Q000378:metabolism; D007700:Kinetics; D008024:Ligands; D008297:Male; D010179:Pancreas / Q000378:metabolism*; D011485:Protein Binding; D011817:Rabbits; D051381:Rats; D017476:Receptors, Neuropeptide Y / Q000037:antagonists & inhibitors*; D015398:Signal Transduction; D012964:Sodium / Q000378:metabolism*
D015220:Calcium Channels; D008024:Ligands; D017476:Receptors, Neuropeptide Y; D012964:Sodium